Isolated Growth Hormone Deficiency: Comprehensive Disease-Characteristics Report

Executive summary

Isolated growth hormone deficiency (IGHD) is deficient secretion or biological availability of pituitary growth hormone (GH) without another pituitary hormone deficiency at presentation. It is the most common childhood pituitary hormone deficiency, with an estimated incidence of 1 per 4,000–10,000 live births; only 3–30% of cases are familial, and most childhood cases are classified as idiopathic. Congenital genetic, structural, acquired, and idiopathic forms all occur. The cardinal pediatric phenotype is proportionate postnatal short stature with reduced height velocity and delayed skeletal maturation. Neonatal disease may instead present with hypoglycemia, prolonged jaundice, or micropenis. Diagnosis remains probabilistic because stimulated GH cutoffs are assay- and protocol-dependent, obesity suppresses test responses, and many children labeled idiopathic do not remain GH deficient when retested after growth completion. Recombinant human GH (rhGH; somatropin) is effective, while weekly long-acting preparations are increasingly used to reduce injection burden. Recent 2023–2024 work has expanded the GH1 variant spectrum, quantified dental abnormalities, developed transcriptomic response predictors, and evaluated oral GH secretagogues and oral macimorelin diagnostic testing. (ibba2024isolatedgrowthhormone pages 1-2, ibba2024isolatedgrowthhormone pages 8-9)

The following table provides a compact structured summary for knowledge-base ingestion.

Table: This compact table summarizes isolated growth hormone deficiency subtypes, core diagnostics, treatments, and mechanistic annotations for structured knowledge-base use. It prioritizes supported identifiers and recent evidence, including 2023-2024 cohorts and active/emerging clinical applications.

1. Disease information

Definition and scope

IGHD is a deficiency of GH production or secretion in which other anterior-pituitary axes are initially intact. “Isolated” describes the hormonal phenotype, not necessarily the cause: disease can be congenital, acquired, or idiopathic, and some patients—especially those with dominant GH1 or pituitary-development variants—subsequently develop multiple pituitary hormone deficiency (MPHD). Consequently, longitudinal endocrine reassessment is essential. (ibba2024isolatedgrowthhormone pages 1-2, ozturk2023phenotypegenotypecorrelationsof pages 2-2, ibba2024isolatedgrowthhormone pages 8-9)

Identifiers and synonyms

• MONDO: isolated congenital growth hormone deficiency, MONDO:0000050; type IA, MONDO:0009876; type IB, MONDO:0013006; type II, MONDO:0008250. Open Targets links MONDO:0000050 most strongly to GH1, RNPC3, and GHRHR. (OpenTargets Search: isolated growth hormone deficiency-GH1,GHRHR,RNPC3)
• OMIM phenotypes: IGHD IA 262400; IGHD IB 612781; IGHD II 173100; IGHD III 307200; GHRHR-related IGHD/“type IV” 618157. Relevant genes include GH1 139250, GHRHR 139191, and GHSR 601898. (ammar2024screeningofghsr pages 1-2)
• MeSH: Dwarfism, Pituitary, D004393, is used in ClinicalTrials.gov indexing, although “dwarfism” is increasingly avoided in person-centered clinical language. (NCT04806854 chunk 1)
• Common synonyms: isolated GHD, IGHD, isolated somatotropin deficiency, isolated pituitary GH deficiency, congenital isolated GHD, familial isolated GHD, and historical “pituitary dwarfism.”
• ICD: routine billing commonly places GHD under ICD-10-CM E23.0, hypopituitarism; that code is not specific for isolated disease. ICD-11 similarly classifies it within hypopituitarism/pituitary hypofunction; local extensions should be verified before database deployment.

This report primarily synthesizes aggregated disease-level resources and published cohorts, not individual EHR records. The 2023–2024 GH1, Egyptian genetics, and dental studies are patient-level research cohorts but are reported here only in aggregate. (huang2024theclinicaland pages 1-2, ammar2024screeningofghsr pages 1-2, torlinskawalkowiak2023developmentalenameldefects pages 1-2)

2. Etiology, risk, and protective factors

Causal factors

1. Congenital genetic disease: pathogenic variants affecting GH synthesis/secretion (GH1), hypothalamic signaling (GHRHR, occasionally GHSR), minor-spliceosome function (RNPC3), or pituitary development (SOX3, BTK, and occasionally POU1F1, PROP1, HESX1, OTX2, GLI2, LHX3/LHX4, SOX2).
2. Congenital structural disease: pituitary hypoplasia, ectopic posterior pituitary, pituitary stalk interruption syndrome (PSIS), or broader midline malformations.
3. Acquired disease: hypothalamic/pituitary tumors, cranial radiotherapy, CNS infection, traumatic brain injury, infiltrative or autoimmune disease, and pituitary surgery. In adults, tumors, surgery, trauma, and radiotherapy predominate. (ibba2024isolatedgrowthhormone pages 1-2, ammar2024screeningofghsr pages 1-2)
4. Idiopathic IGHD: no demonstrable genetic or structural cause; this is the largest pediatric category, but false-positive stimulation testing contributes to diagnostic heterogeneity. (ranke2018growthhormone—pastpresent pages 8-9, ibba2024isolatedgrowthhormone pages 1-2)

Risk factors

• Genetic: family history, consanguinity for recessive disease, X-linked pedigree, or extreme early short stature. Affected relatives may show variable expressivity in dominant GH1 disease. (ozturk2023phenotypegenotypecorrelationsof pages 1-2, ozturk2023phenotypegenotypecorrelationsof pages 2-2)
• Clinical/environmental: cranial irradiation, CNS tumor, severe head trauma, infection, or surgery are causal exposures rather than lifestyle susceptibility factors. Cancer survivors can develop endocrine deficits decades after irradiation, supporting lifelong surveillance. (ibba2024isolatedgrowthhormone pages 1-2)
• Diagnostic modifiers—not causes: obesity, undernutrition, age, sex steroids, pubertal delay, assay choice, and stimulation agent alter measured GH or IGF-1. A 58-study meta-analysis containing 5,135 children found that every one-unit increase in BMI SDS reduced stimulated peak GH by 11.6% (95% CI 8.3–14.8%), creating an overdiagnosis risk. (abawi2021impactofbody pages 1-3)

No reproducible protective genetic alleles, diets, lifestyles, toxins, occupational exposures, smoking effects, infectious triggers, or formal gene–environment interactions have been established for inherited IGHD. Adequate nutrition and treatment of systemic disease prevent phenocopies but do not prevent a pathogenic GH-axis genotype. GHSR-null mice resist diet-induced obesity, but that experimental observation is not evidence for a protective human IGHD intervention. (domene2018geneticmutationsin pages 8-9)

3. Phenotypes

Neonatal and infant disease

Intrauterine growth is usually normal because fetal growth is relatively GH independent, although birth length can be slightly reduced. Neonatal manifestations include recurrent hypoglycemia, prolonged jaundice, lethargy, poor weight gain, frontal bossing, midface hypoplasia, micropenis or genital underdevelopment in males, single central maxillary incisor, and ocular or other midline abnormalities. Severe hypoglycemia can be life-threatening, although isolated disease is often less dramatic than MPHD. Suggested HPO annotations include Short stature, Hypoglycemia, Prolonged neonatal jaundice, Micropenis, Frontal bossing, Midface retrusion, Single maxillary central incisor, and Poor weight gain. (ibba2024isolatedgrowthhormone pages 1-2, ibba2024isolatedgrowthhormone pages 2-4)

Childhood and adolescence

The core phenotype is proportionate short stature—height below −2 SDS—with slow growth velocity, downward crossing of height centiles, delayed bone age, preserved or increased weight-for-height, truncal adiposity, immature facial appearance, depressed nasal bridge, delayed dentition, and sometimes delayed puberty. The disease is generally chronic and progressively increases the height deficit if untreated rather than being episodic. Suggested HPO terms include Proportionate short stature, Growth delay, Delayed skeletal maturation, Delayed dentition, Truncal obesity, and Delayed puberty. (ibba2024isolatedgrowthhormone pages 2-4, ammar2024screeningofghsr pages 1-2)

Genetic severity varies. Type IA commonly produces height below −4.5 SDS, absent GH, and very early growth failure. Types IB and II retain measurable GH and range from mild to severe. In a 2024 Chinese IGHD-II series of six children, mean age was 4.64 ± 1.15 years, mean height −3.95 ± 1.41 SDS, and mean stimulated peak GH 2.83 ± 2.46 ng/mL; four had a family history of short stature. (ibba2024isolatedgrowthhormone pages 4-5, huang2024theclinicaland pages 1-2)

A 2023 cross-sectional study found dental anomalies in 33% of 33 children with isolated GHD versus 4% of 68 controls (p<0.001): hypodontia occurred in 18%, and microdontia/macrodontia in 21%. Developmental enamel defects were not significantly enriched (58% versus 48%). Suggested HPO terms are Hypodontia, Microdontia, Macrodontia, and Abnormality of dental enamel; routine dental assessment is reasonable. (torlinskawalkowiak2023developmentalenameldefects pages 1-2)

Adult and quality-of-life phenotype

Persistent childhood-onset GHD can adversely affect fat/lean-mass distribution, bone acquisition, exercise capacity, cardiac function, lipid metabolism, and quality of life. However, transition studies are heterogeneous, and isolated idiopathic childhood GHD frequently fails confirmation on adult retesting. Adult symptom attribution therefore requires biochemical reconfirmation rather than assuming lifelong disease. (ranke2018growthhormone—pastpresent pages 8-9, ahmid2016growthhormonedeficiency pages 1-3)

Disease-specific EQ-5D or SF-36 statistics for genetically confirmed IGHD remain limited. The dominant pediatric burden comprises short-stature-related psychosocial effects and repeated injections; weekly GH trials explicitly measure interference with daily, social, leisure, and travel activities. (NCT03831880 chunk 1)

4. Genetic and molecular information

Major genes and subtype architecture

• IGHD IA—GH1, autosomal recessive: homozygous deletions or other biallelic null variants eliminate GH. Classic deletion sizes include 6.7, 7.0, 7.6, and 45 kb; the 6.7-kb deletion accounts for an estimated 70–80% of homozygous deletion cases in historical series. Absent endogenous GH prevents immune tolerance, permitting neutralizing anti-GH antibodies and treatment tachyphylaxis. (domene2018geneticmutationsin pages 7-8, ozturk2023phenotypegenotypecorrelationsof pages 2-2)
• IGHD IB—GH1, autosomal recessive: biallelic nonsense, frameshift, or splice variants permit low/bio-inactive GH and usually preserve treatment responsiveness. A 2023 report identified novel homozygous c.162C>G, p.Tyr54*. (ozturk2023phenotypegenotypecorrelationsof pages 1-2)
• IGHD II—GH1, autosomal dominant: splice-site, splice-enhancer, missense, nonsense, and structural variants. IVS3 defects commonly skip exon 3 and produce a 17.5-kDa GH isoform that disrupts secretory-vesicle maturation and injures somatotrophs—a dominant-negative mechanism with variable expressivity. Six 2024 families carried Exon2-5del, c.334T>C, c.291+1G>A, c.291+2T>A, and 1.5- or 1.7-kb deletions; four variants were novel. (domene2018geneticmutationsin pages 7-8, huang2024theclinicaland pages 1-2)
• IGHD III—SOX3 or BTK, X-linked: may include MPHD, ectopic posterior pituitary, intellectual disability, immune dysfunction, and BTK-related agammaglobulinemia. This category is biologically heterogeneous and may not remain strictly isolated. (ibba2024isolatedgrowthhormone pages 10-12, ibba2024isolatedgrowthhormone pages 4-5)
• GHRHR-related/type IV, autosomal recessive: loss of receptor signaling causes somatotroph under-stimulation and pituitary hypoplasia. The recurrent c.57+1G>A splice variant causes intron retention and premature termination; signal-peptide variants can block receptor trafficking to the cell surface. (domene2018geneticmutationsin pages 7-8, ibba2024isolatedgrowthhormone pages 10-12)
• RNPC3-related/type V, autosomal recessive: defective U12-type minor-spliceosome processing produces severe postnatal growth failure, absent GH, low IGF-1/IGFBP-3, anterior-pituitary hypoplasia, low-normal prolactin, and sometimes ovarian insufficiency. Primary evidence is PMID 24480542. (OpenTargets Search: isolated growth hormone deficiency-GH1,GHRHR,RNPC3, ibba2024isolatedgrowthhormone pages 4-5)
• GHSR: rare dominant or recessive loss-of-function variants reduce ghrelin-receptor constitutive/ligand-dependent signaling. A 2024 Egyptian cohort identified GHRHR NM_000823.4:c.1069C>T, p.Arg357Cys and novel GHSR NM_198407.2:c.1043dup, p.Ser349Leufs*6 in separate patients. (ammar2024screeningofghsr pages 1-2)

Variants are germline; there is no established somatic IGHD category. Pathogenic deletions and truncating/splice variants should be classified using ACMG/AMP evidence, segregation, phenotype, functional data, and population frequency. Exact gnomAD frequencies are variant-specific and should be pulled at ingestion time; causal severe-IGHD alleles are generally absent or exceptionally rare. The cited 2023 panel study used ACMG classification, ClinVar/dbSNP/HGMD review, and segregation testing. (ozturk2023phenotypegenotypecorrelationsof pages 1-2)

No consistently validated human modifier gene, protective allele, anticipation, or epigenetic signature is ready for clinical annotation. Dominant GH1 disease shows incomplete/variable expression, and digenic pituitary-development interactions are plausible, but evidence remains family- and model-specific. Germline mosaicism is theoretically possible but not a prominent documented feature. Founder GHRHR mutations occur in geographically isolated/consanguineous populations, so local carrier frequencies can be much higher than global frequencies.

5. Environmental and lifestyle information

There is no evidence that ordinary diet, exercise, smoking, alcohol, pollution, occupational exposure, or a specific infectious agent causes hereditary IGHD. CNS infection, trauma, tumors, surgery, and ionizing radiation can cause acquired isolated GHD by damaging hypothalamic GHRH neurons, the pituitary stalk, or somatotrophs. Chronic malnutrition, renal disease, inflammation, hypothyroidism, and glucocorticoid exposure alter GH/IGF-1 physiology and must be treated or excluded as mimics. Exercise, nutrition, gonadal steroids, thyroid hormone, ghrelin, glucocorticoids, and systemic illness modulate secretion but do not constitute established inherited-disease prevention targets. (ibba2024isolatedgrowthhormone pages 1-2, ibba2024isolatedgrowthhormone pages 2-4, ammar2024screeningofghsr pages 1-2)

6. Mechanism and pathophysiology

Causal chain

Upstream regulation: hypothalamic GHRH stimulates and somatostatin inhibits anterior-pituitary somatotrophs; ghrelin/GHSR augments secretion. GH is released in pulses and is regulated by IGF-1 negative feedback. GHRHR/GHSR defects reduce somatotroph stimulation; developmental-gene defects reduce pituitary/somatotroph formation; GH1 variants abolish synthesis, generate inactive hormone, or exert dominant-negative secretory toxicity; RNPC3 disrupts minor-intron splicing. (ranke2018growthhormone—pastpresent pages 5-6, tidblad2022thehistoryphysiology pages 2-3)

Downstream signaling: circulating GH binds dimeric GHR, activates JAK2 and STAT5B, and drives hepatic and tissue transcription of IGF1, IGFBP3, IGFALS, and related targets. IGF-1 circulates largely in an IGF-1–IGFBP-3–ALS ternary complex. Reduced GH therefore lowers IGF-1 bioavailability and direct GH action. (ranke2018growthhormone—pastpresent pages 5-6, ranke2018growthhormone—pastpresent pages 6-7)

Clinical translation: reduced GH/IGF-1 signaling decreases recruitment and proliferation of growth-plate progenitors/chondrocytes and hypertrophic-cell expansion, causing slow longitudinal growth and delayed skeletal maturation. Reduced lipolysis and protein anabolism contribute to truncal adiposity and low lean mass; impaired osteoblast/chondrocyte stimulation compromises bone accrual. GH also influences tooth-cell differentiation through BMP2/BMP4 and TGF-family signaling. (ibba2024isolatedgrowthhormone pages 5-6, tidblad2022thehistoryphysiology pages 2-3, torlinskawalkowiak2023developmentalenameldefects pages 1-2)

Suggested annotations include GO: growth hormone secretion; regulation of growth hormone secretion; JAK–STAT cascade involved in growth hormone signaling; insulin-like growth factor receptor signaling; chondrocyte proliferation; endochondral ossification; lipid catabolic process; skeletal-system development; mRNA splicing via spliceosome. Relevant CL terms are somatotroph, hepatocyte, chondrocyte, osteoblast, hypothalamic neurosecretory neuron, and adipocyte.

Immune, tissue damage, and omics

IGHD is not ordinarily inflammatory or autoimmune. Immune involvement is subtype-specific in BTK-related X-linked agammaglobulinemia, and anti-GH antibodies can neutralize replacement in type IA. Dominant 17.5-kDa GH can cause somatotroph loss/apoptosis and anterior-pituitary hypoplasia. (ozturk2023phenotypegenotypecorrelationsof pages 2-2, domene2018geneticmutationsin pages 8-9)

A 2024 study reported that pretreatment blood transcriptomic signatures predicted first-year response to daily rhGH or weekly somapacitan, but external validation is required. Disease-specific proteomics, metabolomics, lipidomics, single-cell atlases, spatial transcriptomics, CRISPR screens, and integrated multi-omics are not yet mature clinical tools. (ibba2024isolatedgrowthhormone pages 12-13, ibba2024isolatedgrowthhormone pages 5-6)

7. Anatomical structures affected

• Primary: hypothalamus, pituitary stalk, and anterior pituitary/somatotroph population. Suggested UBERON terms: hypothalamus, pituitary stalk, pituitary gland, anterior lobe of pituitary gland.
• Secondary targets: liver (IGF-1/IGFBP-3/ALS production), epiphyseal growth plate, bone, skeletal muscle, adipose tissue, heart, and developing teeth.
• Subcellular: plasma membrane GHRHR/GHSR/GHR; ER/Golgi and secretory granules for GH folding/trafficking; cytosolic JAK2/STAT5B; nucleus for target transcription; spliceosome for RNPC3 disease.
• Imaging: pituitary hypoplasia is the most frequent abnormality; PSIS and ectopic posterior pituitary are less common. A small pituitary alone is not diagnostic, and GH1/GHRHR disease can have a normal MRI. There is no relevant lateralization. (ibba2024isolatedgrowthhormone pages 4-5)

8. Temporal development and natural history

Congenital disease begins biologically at birth but commonly becomes clinically obvious at 2–4 years, when postnatal growth decelerates. Severe IA or structural disease can present neonatally. Untreated disease produces chronic, progressive height deficit and delayed maturation; it is not relapsing-remitting. Puberty may be delayed but fertility is usually preserved in genuinely isolated disease. (ammar2024screeningofghsr pages 1-2, torlinskawalkowiak2023developmentalenameldefects pages 1-2)

The principal intervention window is before major growth-plate senescence; younger treatment initiation and longer therapy predict better adult height. Therapy generally continues until growth velocity is below 2 cm/year and/or bone maturation is complete. Idiopathic isolated cases should then be retested because many normalize; proven genetic/structural severe disease is more likely permanent. Type II and developmental-gene cases require surveillance for evolving TSH, ACTH, gonadotropin, or prolactin deficits. (ranke2018growthhormone—pastpresent pages 8-9, ranke2021shortandlongterm pages 9-10, ibba2024isolatedgrowthhormone pages 8-9, ibba2024isolatedgrowthhormone pages 5-6)

9. Inheritance and population characteristics

Incidence estimates are 1:4,000–10,000 live births; a UK estimate for congenital childhood-onset GHD was approximately 1:3,500–4,000. Robust IGHD-specific point prevalence and annual incidence by country, ethnicity, or sex are unavailable. Referral and treatment are male-skewed: in one 10,125-child referral cohort, only 35% were female, and GH stimulation testing occurred in 13.1% of males versus 10.6% of females, suggesting ascertainment bias rather than biological sex restriction. (ibba2024isolatedgrowthhormone pages 1-2, ahmid2016growthhormonedeficiency pages 1-3)

Inheritance is AR for IA, IB, GHRHR-related IV, and RNPC3-related V; AD for II and some GHSR disease; and X-linked for III. Penetrance and expressivity are especially variable in AD GH1 disease. Consanguinity increases recessive-disease probability. No anticipation is known. Carrier frequency and variant geography must be calculated per allele/population; no defensible universal carrier rate exists. (ozturk2023phenotypegenotypecorrelationsof pages 1-2, ibba2024isolatedgrowthhormone pages 4-5)

10. Diagnostics

Clinical and biochemical workflow

1. Confirm serial auxology: height below −2 SDS, height relative to mid-parental target, reduced growth velocity, and centile crossing. A fall in height SDS exceeding 0.25 over one year is a strong growth-disorder signal; height velocity above −1 SDS makes severe non-acquired GHD less likely. Obtain left-hand/wrist bone age. (ranke2021shortandlongterm pages 3-4)
2. Exclude systemic/nutritional/endocrine causes with history, examination, CBC, inflammatory/renal/hepatic testing as indicated, thyroid testing, celiac screening, and nutritional assessment.
3. Measure age-, sex-, and puberty-adjusted IGF-1 and IGFBP-3. IGF-1 below −2 SDS supports GHD, but a normal result does not exclude it; IGFBP-3 is relatively more useful under age three. In an 800-subject study, the best IGF-1 threshold was −1.5 SDS, sensitivity 67.61%, specificity 62.62%, and AUC 0.69; performance was poorer for idiopathic GHD (AUC 0.63) than organic/genetic disease (0.75). (ibba2020igf1forthe pages 1-2, ibba2024isolatedgrowthhormone pages 2-4)
4. In most children, require inadequate responses to two different GH stimulation tests—for example clonidine, arginine, glucagon, or insulin tolerance testing where safe. Cutoffs vary approximately 3–10 µg/L; a modern guideline/study threshold of 7 µg/L is common, but results must be interpreted with the assay and agent rather than as a universal biological boundary. Basal random GH is generally useless because secretion is pulsatile. (ibba2024isolatedgrowthhormone pages 2-4, ibba2020igf1forthe pages 1-2, tran2023somatropinforgrowth pages 35-37)
5. Account for BMI and puberty. The BMI meta-analysis proposed, for nominal cutoffs of 5, 7, 10, and 20 µg/L, overweight-child cutoffs of 4.6, 6.5, 9.3, 18.6 and obesity cutoffs of 4.3, 6.0, 8.6, 17.3 µg/L, respectively; these are evidence-based proposals, not universally adopted standards. Sex-steroid priming is recommended before testing prepubertal boys older than 11 and girls older than 10 to reduce false positives. (abawi2021impactofbody pages 1-3, ibba2024isolatedgrowthhormone pages 1-2)
6. Obtain hypothalamic–pituitary MRI after biochemical confirmation to detect tumor, hypoplasia, PSIS, or ectopic posterior pituitary. MRI may reasonably precede GHST in very young children in whom testing is unreliable or hazardous. (ibba2024isolatedgrowthhormone pages 4-5)

Exceptions and neonatal diagnosis

Formal GHST is unnecessary when auxological evidence coexists with a structural hypothalamic-pituitary lesion and at least one other pituitary deficit. In neonates with hypoglycemia, GH ≤5 ng/mL together with another pituitary deficiency or the classical MRI triad strongly supports diagnosis. A dried-blood-spot GH below 7 µg/L plus recurrent hypoglycemia/MPHD/significant malformation showed high reliability in one study, but newborn-card testing is not validated for population screening. (ibba2024isolatedgrowthhormone pages 2-4, tran2023somatropinforgrowth pages 35-37)

Genetic testing

Testing is most indicated for severe/extreme early short stature, family history, consanguinity, normal MRI with severe biochemical disease, structural/midline abnormalities, immune findings, or evolving MPHD. A practical sequence is: GH1 deletion/duplication analysis (MLPA/CNV) plus sequencing; GHRHR; GHSR; RNPC3; SOX3/BTK when phenotype suggests; then a broader pituitary/short-stature panel or trio WES/WGS. A 2023 study used a 25-gene panel with 99.2% coverage, followed by MLPA and segregation testing. CMA is useful for syndromic structural disease/CNVs; karyotype is appropriate for Turner syndrome in girls. FISH, mitochondrial sequencing, repeat-expansion testing, biopsy, electrophysiology, and liquid biopsy are not routine IGHD tests. (ibba2024isolatedgrowthhormone pages 4-5, ozturk2023phenotypegenotypecorrelationsof pages 1-2)

Differential diagnosis

Exclude familial short stature, constitutional delay of growth and puberty, small-for-gestational-age growth failure, malnutrition, celiac/inflammatory/renal disease, hypothyroidism, glucocorticoid excess, psychosocial deprivation, Turner syndrome, SHOX deficiency, Noonan/3M syndromes, skeletal dysplasia, GH insensitivity (GHR, STAT5B, IGF1, IGFALS), and chronic medication effects. GH neurosecretory dysfunction—low spontaneous secretion but normal stimulated peak—remains controversial. (ranke2018growthhormone—pastpresent pages 8-9)

There is no population newborn screening. Cascade testing and targeted testing of relatives are appropriate after a pathogenic familial variant is identified.

11. Outcome and prognosis

IGHD is treatable and is not ordinarily directly lethal. Disease-specific 5- or 10-year survival estimates are not meaningful. Prognosis chiefly concerns adult height, metabolic/body-composition health, bone acquisition, treatment burden, and evolution to MPHD. Historical rhGH-era patients starting near −2.9 height SDS achieved final height around −1.4 SDS; modern earlier daily treatment often reaches the lower-normal target range. Favorable predictors are younger age, taller baseline/target height, longer treatment, appropriate dose, adherence, and strong first-year response. (ranke2021shortandlongterm pages 9-10)

In the 2024 IGHD-II series, four treated children gained 1.21 ± 0.30 height SDS at six months and 1.79 ± 0.15 SDS at one year, illustrating high responsiveness in a small genetic cohort. Poor response may be defined operationally as first-year height-SDS gain below 0.4 or height velocity below −1 SDS relative to age/sex treatment targets. (huang2024theclinicaland pages 1-2, ibba2024isolatedgrowthhormone pages 5-6)

Long-term untreated persistent GHD may impair body composition, skeletal health, exercise capacity, and quality of life. Evidence for transition-age GH benefits is inconsistent, so persistent deficiency should be confirmed before indefinite adult therapy. (ahmid2016growthhormonedeficiency pages 1-3)

12. Treatment and current implementation

Daily rhGH

Subcutaneous recombinant human GH (somatropin) is standard of care. A suggested pediatric starting dose is 22–35 µg/kg/day or 0.16–0.24 mg/kg/week, individualized by weight, growth velocity, response, adherence, and IGF-1. Review every 3–6 months; maintain IGF-1 in the age-/sex-appropriate range and monitor thyroid and adrenal function because GH can unmask central hypothyroidism or adrenal insufficiency. Routine pubertal dose escalation is not recommended. Suggested NCIT intervention terms are Somatropin and Recombinant Human Growth Hormone Therapy. (ibba2024isolatedgrowthhormone pages 5-6)

Treatment increases growth rate and adult height, lowers fat mass, increases lean/bone mass, stimulates skeletal IGF-1, chondrocytes, osteoblasts, and bone remodeling. Type IB, II, GHRHR, and RNPC3 disease generally responds well; IA can develop neutralizing antibodies and tachyphylaxis. There is no established pharmacogenomic dosing guideline, although genotype informs permanence and antibody risk. (ibba2024isolatedgrowthhormone pages 4-5, ibba2024isolatedgrowthhormone pages 5-6)

Weekly long-acting GH

Approved pediatric weekly products include:

• Somatrogon, a GH–hCG-carboxy-terminal-peptide fusion, first approved in Australia in 2021 and subsequently in Europe, the United States, Canada, Japan, and other jurisdictions.
• Somapacitan, an albumin-binding GH analog, first approved in Europe in 2021 and subsequently in multiple countries.
• Lonapegsomatropin, a transiently PEG-bound prodrug, FDA-approved in 2021.
• Jintrolong, PEGylated GH approved in China since 2014.
• Eutropin Plus/LBO3002, a depot formulation available in South Korea.

Trials and meta-analyses generally find non-inferior growth and broadly similar short-term safety to daily rhGH, with lower injection burden; post-marketing surveillance remains necessary. A Pfizer crossover study, NCT03831880, enrolled 87 children to compare somatrogon versus daily Genotropin treatment burden. (ibba2024isolatedgrowthhormone pages 6-8, NCT03831880 chunk 1)

Safety

Common or important monitored events include transient headache, intracranial hypertension, slipped capital femoral epiphysis, scoliosis progression during rapid growth, edema/arthralgia, glucose intolerance, and rare pancreatitis or sleep-apnea exacerbation. New primary malignancy has not been shown to increase in otherwise low-risk GHD children; concern is greater for secondary neoplasms in previously irradiated cancer survivors. The KIGS cohort included 83,803 treated children and found no unexpected safety signal. SAGhE analyses did not establish a consistent dose-related mortality association, although continued surveillance is appropriate. (ibba2024isolatedgrowthhormone pages 8-9, ibba2024isolatedgrowthhormone pages 6-8)

Experimental and diagnostic trials

• LUM-201, an oral GH secretagogue, is intended for selected idiopathic pediatric GHD with residual pituitary reserve—not severe absent secretion or organic disease. Phase 2 OraGrowtH210, NCT04614337, randomized 104 children among 0.8, 1.6, or 3.2 mg/kg/day and daily rhGH; OraGrowtH212, NCT04806854, studies 1.6 versus 3.2 mg/kg/day and GH pulsatility in approximately 24 children. (NCT04806854 chunk 1, NCT04614337 chunk 1)
• Macimorelin: phase 3 DETECT, NCT04786873, completed June 13, 2024, enrolled 101 patients aged 2–<18 years and compared two oral macimorelin GHSTs with arginine and clonidine, assessing ROC AUC, sensitivity, specificity, and repeatability. It was diagnostic, not therapeutic. (NCT04786873 chunk 1)
• Y-shaped PEGylated somatropin, NCT04513171: completed phase 2/3 study of 434 prepubertal children, comparing weekly 100–140 µg/kg with daily Norditropin; 52-week height velocity was the phase 3 primary endpoint. (NCT04513171 chunk 1)

No gene, cell, RNA, CRISPR, surgical, or immunotherapy is established for hereditary IGHD. Surgery/radiotherapy applies only to an underlying acquired lesion, not hormone deficiency itself. Nutrition, psychosocial support, dental care, and adherence support are useful adjuncts.

13. Prevention

• Primary prevention: inherited IGHD generally cannot be prevented. Avoid unnecessary cranial irradiation and optimize CNS-tumor/trauma care where possible. Vaccines or antimicrobial prophylaxis have no IGHD-specific role.
• Secondary prevention: serial height measurement and growth-velocity surveillance permit early recognition; targeted monitoring is warranted after cranial irradiation, CNS tumors, trauma, or in affected families. There is no universal newborn screen.
• Genetic prevention options: counseling, cascade testing, carrier testing for a known familial AR variant, prenatal diagnosis, and preimplantation genetic testing may be offered with nondirective counseling.
• Tertiary prevention: timely rhGH, adherence support, IGF-1 and thyroid/adrenal monitoring, orthopedic/ophthalmologic review when symptomatic, dental screening, and transition retesting reduce permanent short stature, metabolic morbidity, and treatment complications. (ibba2024isolatedgrowthhormone pages 5-6, torlinskawalkowiak2023developmentalenameldefects pages 1-2)

14. Other species and natural disease

Relevant taxa include Mus musculus (NCBI Taxon 10090) and Danio rerio (7955). Robust retrieved evidence supports experimental/spontaneous models rather than a well-curated naturally occurring veterinary counterpart. Claims of breed-specific canine, feline, cattle, or chicken IGHD should therefore be verified in OMIA/VBO before knowledge-base inclusion. The disorder is noninfectious and nonzoonotic; transmission is genetic, not cross-species. (domene2018geneticmutationsin pages 8-9, domene2018geneticmutationsin pages 7-8)

15. Model organisms

• Little/lit mouse: spontaneous homozygous Ghrhr p.Asp60Gly abolishes ligand binding, lowers GH and IGF-1, and causes severe recessive dwarfism, closely modeling GHRHR-related IGHD. It is useful for testing hypothalamic–somatotroph signaling and replacement; limitations include species-specific growth dynamics. (domene2018geneticmutationsin pages 8-9)
• 17.5-kDa GH transgenic mouse: models dominant exon-3-skipping GH1 disease, with abnormal secretory vesicles, somatotroph loss, and anterior-pituitary hypoplasia. It is particularly informative for dominant-negative cellular toxicity. (domene2018geneticmutationsin pages 8-9)
• Ghrh-targeted and somatotroph-ablation mice: isolate the consequences of absent hypothalamic ligand or GH-producing cells. Snell/Pou1f1 and Ames/Prop1 mice model MPHD rather than pure IGHD and therefore have hypothyroidism, infertility, or other confounders. (domene2018geneticmutationsin pages 16-17, domene2018geneticmutationsin pages 5-7)
• Ghsr knockout mice: have modestly reduced IGF-1/body weight but are not profoundly dwarf, illustrating that human GHSR disease is often partial and that receptor redundancy/species differences matter. (domene2018geneticmutationsin pages 8-9)
• Zebrafish vizzini gh1 mutant: has persistent small size, severe growth retardation, and increased adiposity, reproducing growth and metabolic aspects of IGHD. Zebrafish btk knockdown causes broader embryonic abnormalities and is less specific. (domene2018geneticmutationsin pages 7-8)

Useful resources are MGI/IMSR/MMRRC for mice and ZFIN for zebrafish. These models robustly reproduce impaired growth and selected metabolic/pituitary features but do not fully capture human psychosocial burden, pubertal timing, antibody formation, adult-height outcomes, or heterogeneous idiopathic disease.

Evidence gaps and interpretation cautions

The 2024 disease-specific review states directly that GHST accuracy remains debated because of “arbitrarily established cut-off, non-physiological test procedures, variability in the type of stimulation test and type of assay.” It also concludes that “IGHD may progress to MPHD,” justifying long-term pituitary surveillance. (ibba2024isolatedgrowthhormone pages 1-2, ibba2024isolatedgrowthhormone pages 8-9)

Major unresolved areas are: validated diagnostic cutoffs adjusted simultaneously for assay, agent, BMI, age, and puberty; population-specific prevalence and carrier frequencies; prospective quality-of-life and cardiovascular outcomes in molecularly confirmed IGHD; robust genotype-specific treatment algorithms; long-term comparative safety of weekly GH; validated transcriptomic response prediction; and disease-specific single-cell, spatial, proteomic, metabolomic, or epigenomic datasets. The evidence base is strongest for auxology, GH1/GHRHR mechanisms, replacement efficacy, and short-term LAGH non-inferiority, and weaker for idiopathic partial GHD and lifelong adult treatment.

Key recent sources and links

• Ibba A, et al. “Isolated Growth Hormone Deficiency.” Published 8 August 2024. https://doi.org/10.3390/endocrines5030025 (ibba2024isolatedgrowthhormone pages 1-2)
• Huang X, et al. GH1 variants and IGHD II in six families. Published 7 October 2024. https://doi.org/10.3389/fendo.2024.1363050 (huang2024theclinicaland pages 1-2)
• Ammar THA, et al. GHSR, GHRHR, and GH1 screening in Egyptian IGHD. Published 2024. https://doi.org/10.1186/s43042-024-00480-y (ammar2024screeningofghsr pages 1-2)
• Öztürk AP, et al. GH1 phenotype–genotype correlations. Published online 14 June 2023. https://doi.org/10.1159/000531113 (ozturk2023phenotypegenotypecorrelationsof pages 1-2)
• Torlińska-Walkowiak N, et al. Dental anomalies in isolated GHD. Published September 2023. https://doi.org/10.1038/s41598-023-41892-x (torlinskawalkowiak2023developmentalenameldefects pages 1-2)
• ClinicalTrials.gov: NCT04786873 (pediatric macimorelin), NCT04614337 and NCT04806854 (LUM-201), NCT04513171 (weekly PEGylated GH). (NCT04513171 chunk 1, NCT04806854 chunk 1, NCT04786873 chunk 1, NCT04614337 chunk 1)

References

1. (ibba2024isolatedgrowthhormone pages 1-2): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

2. (ibba2024isolatedgrowthhormone pages 8-9): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

3. (ibba2024isolatedgrowthhormone pages 2-4): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

4. (domene2018geneticmutationsin pages 7-8): S. Domené and H. Domené. Genetic mutations in the gh/igf axis. Pediatric endocrinology reviews : PER, 16 Suppl 1:39-62, Sep 2018. URL: https://doi.org/10.17458/per.vol16.2018.dd.geneticmutationsghigf, doi:10.17458/per.vol16.2018.dd.geneticmutationsghigf. This article has 20 citations.

5. (ibba2024isolatedgrowthhormone pages 4-5): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

6. (ozturk2023phenotypegenotypecorrelationsof pages 1-2): A. Öztürk, A. Aslanger, F. Baş, G. Toksoy, V. Karaman, Gulandam Bagırova, S. Poyrazoglu, Z. Uyguner, F. Darendeliler, and Zehra Yavaş Abalı. Phenotype-genotype correlations of gh1 gene variants in patients with isolated growth hormone deficiency or multiple pituitary hormone deficiency. Hormone Research in Pædiatrics, 97:126-133, Jun 2023. URL: https://doi.org/10.1159/000531113, doi:10.1159/000531113. This article has 7 citations.

7. (ozturk2023phenotypegenotypecorrelationsof pages 2-2): A. Öztürk, A. Aslanger, F. Baş, G. Toksoy, V. Karaman, Gulandam Bagırova, S. Poyrazoglu, Z. Uyguner, F. Darendeliler, and Zehra Yavaş Abalı. Phenotype-genotype correlations of gh1 gene variants in patients with isolated growth hormone deficiency or multiple pituitary hormone deficiency. Hormone Research in Pædiatrics, 97:126-133, Jun 2023. URL: https://doi.org/10.1159/000531113, doi:10.1159/000531113. This article has 7 citations.

8. (huang2024theclinicaland pages 1-2): Xiaozhen Huang, Hong Chen, Huakun Shangguan, Wenyong Wu, Zhuanzhuan Ai, Zhifeng Chen, and Ruimin Chen. The clinical and genetic aspects of six individuals with gh1 variants and isolated growth hormone deficiency type ii. Frontiers in Endocrinology, Oct 2024. URL: https://doi.org/10.3389/fendo.2024.1363050, doi:10.3389/fendo.2024.1363050. This article has 4 citations.

9. (ibba2024isolatedgrowthhormone pages 10-12): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

10. (domene2018geneticmutationsin pages 8-9): S. Domené and H. Domené. Genetic mutations in the gh/igf axis. Pediatric endocrinology reviews : PER, 16 Suppl 1:39-62, Sep 2018. URL: https://doi.org/10.17458/per.vol16.2018.dd.geneticmutationsghigf, doi:10.17458/per.vol16.2018.dd.geneticmutationsghigf. This article has 20 citations.

11. (OpenTargets Search: isolated growth hormone deficiency-GH1,GHRHR,RNPC3): Open Targets Query (isolated growth hormone deficiency-GH1,GHRHR,RNPC3, 10 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

12. (ammar2024screeningofghsr pages 1-2): Tamer H. A. Ammar, Ghada M. M. Al-Ettribi, Maha M. A. Abo Hashish, Tarek M. Farid, Amany A. Abou-Elalla, and Manal M. Thomas. Screening of ghsr, ghrhr, gh1 genes in isolated growth hormone deficiency disease in egyptian patients. Egyptian Journal of Medical Human Genetics, Feb 2024. URL: https://doi.org/10.1186/s43042-024-00480-y, doi:10.1186/s43042-024-00480-y. This article has 11 citations and is from a peer-reviewed journal.

13. (abawi2021impactofbody pages 1-3): Ozair Abawi, Dieuwertje Augustijn, Sanne E. Hoeks, Yolanda B. de Rijke, and Erica L. T. van den Akker. Impact of body mass index on growth hormone stimulation tests in children and adolescents: a systematic review and meta-analysis. Critical Reviews in Clinical Laboratory Sciences, 58:576-595, Aug 2021. URL: https://doi.org/10.1080/10408363.2021.1956423, doi:10.1080/10408363.2021.1956423. This article has 40 citations and is from a peer-reviewed journal.

14. (ibba2024isolatedgrowthhormone pages 5-6): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

15. (ranke2021shortandlongterm pages 9-10): Michael B. Ranke. Short and long-term effects of growth hormone in children and adolescents with gh deficiency. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.720419, doi:10.3389/fendo.2021.720419. This article has 86 citations.

16. (ibba2024isolatedgrowthhormone pages 6-8): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

17. (NCT04614337 chunk 1): Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial). Lumos Pharma. 2020. ClinicalTrials.gov Identifier: NCT04614337

18. (NCT04806854 chunk 1): PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212). Lumos Pharma. 2021. ClinicalTrials.gov Identifier: NCT04806854

19. (NCT04786873 chunk 1): A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is. AEterna Zentaris. 2021. ClinicalTrials.gov Identifier: NCT04786873

20. (ranke2018growthhormone—pastpresent pages 5-6): MB Ranke and JM Wit. Growth hormone—past, present and future. Unknown journal, 2018.

21. (tidblad2022thehistoryphysiology pages 2-3): Anders Tidblad. The history, physiology and treatment safety of growth hormone. Jun 2022. URL: https://doi.org/10.1111/apa.15948, doi:10.1111/apa.15948. This article has 54 citations and is from a peer-reviewed journal.

22. (ranke2018growthhormone—pastpresent pages 6-7): MB Ranke and JM Wit. Growth hormone—past, present and future. Unknown journal, 2018.

23. (torlinskawalkowiak2023developmentalenameldefects pages 1-2): Natalia Torlińska-Walkowiak, Katarzyna A. Majewska, Anna Sowińska, Andrzej Kędzia, and Justyna Opydo-Szymaczek. Developmental enamel defects and dental anomalies of number and size in children with growth hormone deficiency. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-41892-x, doi:10.1038/s41598-023-41892-x. This article has 22 citations and is from a peer-reviewed journal.

24. (ranke2018growthhormone—pastpresent pages 8-9): MB Ranke and JM Wit. Growth hormone—past, present and future. Unknown journal, 2018.

25. (ahmid2016growthhormonedeficiency pages 1-3): M. Ahmid, C. Perry, Syed Faisal Ahmed, and M. Shaikh. Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement. Endocrine Connections, 5:R1-R11, May 2016. URL: https://doi.org/10.1530/ec-16-0024, doi:10.1530/ec-16-0024. This article has 44 citations and is from a peer-reviewed journal.

26. (NCT03831880 chunk 1): Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD. Pfizer. 2019. ClinicalTrials.gov Identifier: NCT03831880

27. (ibba2024isolatedgrowthhormone pages 12-13): Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, and Sandro Loche. Isolated growth hormone deficiency. Endocrines, 5:341-353, Aug 2024. URL: https://doi.org/10.3390/endocrines5030025, doi:10.3390/endocrines5030025. This article has 2 citations.

28. (ranke2021shortandlongterm pages 3-4): Michael B. Ranke. Short and long-term effects of growth hormone in children and adolescents with gh deficiency. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.720419, doi:10.3389/fendo.2021.720419. This article has 86 citations.

29. (ibba2020igf1forthe pages 1-2): Anastasia Ibba, Francesca Corrias, Chiara Guzzetti, Letizia Casula, Mariacarolina Salerno, Natascia di Iorgi, Gianluca Tornese, Giuseppa Patti, Giorgio Radetti, Mohamad Maghnie, Marco Cappa, and Sandro Loche. Igf1 for the diagnosis of growth hormone deficiency in children and adolescents: a reappraisal. Nov 2020. URL: https://doi.org/10.1530/ec-20-0347, doi:10.1530/ec-20-0347. This article has 56 citations and is from a peer-reviewed journal.

30. (tran2023somatropinforgrowth pages 35-37): Khai Tran and Alexandra Grobelna. Somatropin for growth hormone deficiency. Canadian Journal of Health Technologies, Aug 2023. URL: https://doi.org/10.51731/cjht.2023.708, doi:10.51731/cjht.2023.708. This article has 2 citations.

31. (NCT04513171 chunk 1): Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children. Xiamen Amoytop Biotech Co., Ltd.. 2018. ClinicalTrials.gov Identifier: NCT04513171

32. (domene2018geneticmutationsin pages 16-17): S. Domené and H. Domené. Genetic mutations in the gh/igf axis. Pediatric endocrinology reviews : PER, 16 Suppl 1:39-62, Sep 2018. URL: https://doi.org/10.17458/per.vol16.2018.dd.geneticmutationsghigf, doi:10.17458/per.vol16.2018.dd.geneticmutationsghigf. This article has 20 citations.

33. (domene2018geneticmutationsin pages 5-7): S. Domené and H. Domené. Genetic mutations in the gh/igf axis. Pediatric endocrinology reviews : PER, 16 Suppl 1:39-62, Sep 2018. URL: https://doi.org/10.17458/per.vol16.2018.dd.geneticmutationsghigf, doi:10.17458/per.vol16.2018.dd.geneticmutationsghigf. This article has 20 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.17458/per.vol16.2018.dd.geneticmutationsghigf (9 mentions) - Identifier did not resolve to a record